期刊文献+

胸苷酸合成酶基因5′-端非翻译区域多态性在肺癌诊疗中的应用 被引量:1

下载PDF
导出
摘要 目的探讨胸苷酸合成酶(TS)基因5′-端非翻译区域(5′-UTR)多态性在肺癌诊疗中的应用效果。方法回顾性分析2018年8月至2019年6月50例非小细胞肺癌患者临床资料,所有患者均实施顺铂化学治疗方案,化学治疗2~3个周期后对其临床化学治疗总有效率进行评价,根据其化学治疗效果的不同分为A组(化学治疗敏感性高,25例),B组(化学治疗敏感性低,25例),2组均使用聚合酶链式反应-限制性片段长度多态性(PCR-RFLP)技术对TS基因5′-UTR多态性进行检测,比较化学治疗敏感性与TS基因5′-UTR多态性与化学治疗敏感性及化学治疗毒性反应的关系。结果A组中TS基因5′-UTR2R/3R+2R/2R的分布率80%(20/25)明显高于B组48%(12/25),差异有统计学意义(P<0.05);非小细胞肺癌患者中TS基因5′-UTR2R/3R+2R/2R对化学治疗的毒性反应明显高于携带TS基因5′-UTR3R/3R,差异有统计学意义(P<0.05)。结论TS基因5′-UTR2R/3R+2R/2R在化学治疗效果较好的患者中有着较为广泛的分布,并且TS基因5′-UTR3R/3R者对铂类化学治疗具有较强的耐药性。
出处 《实用医技杂志》 2020年第3期305-307,共3页 Journal of Practical Medical Techniques
  • 相关文献

参考文献6

二级参考文献51

  • 1邹小农.中国肺癌流行病学[J].中华肿瘤防治杂志,2007,14(12):881-883. 被引量:151
  • 2Cancer Genome Atlas Research Network. Comprehensive ge- nomic characterization of squamous cell lung cancers[J]. Nature,2012,489 (7 417 ) :519 - 525.
  • 3A1-Saleh K, Quinton C, Ellis PM. Role of pemetrexed in ad- vanced non-small-cell lung cancer : meta-analysis of random- ized controlled trials, with histology subgroup analysis [ J ]. Curr Oncol,2012,19 ( 1 ) : e9 - el5.
  • 4Pallis AG, Georgoulias V. Is there a standard regimen for first-line treatment of advanced/metastatic non-small-ceil lung cancer? What has meta-analyses contributed to today's standard of care [ J 1. Lung Cancer,2012,75 (3) :269 - 274.
  • 5Yoshioka H, Okamoto I, Morita S, et al. Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with ad- vanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study [ J ]. Ann Oncol, 2013,24(5) :1 326- 1 331.
  • 6Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance ther- apy with pemetrexed plus best supportive care versus place- bo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non- small-cell lung cancer ( PARAMOUNT ) : a double-blind, phase 3, randomised controlled trial [ J ]. Lancet Oncol, 2012,13 (3) :247 - 255.
  • 7Nishino M, Cryer SK, Okajima Y, et al. Tumoral cavitation in patients with non-small-cell lung cancer treated with antian- giogenic therapy using bevacizumab [ J ]. Cancer Imaging, 2012,12 ( 1 ) :225 - 235.
  • 8Belani CP, Wu YL, Chen YM, et al. Efficacy and safety of pemetrexed maintenance therapy versus best supportive care in patients from East Asia with advanced, nonsquamous non- small cell lung cancer : an exploratory subgroup analysis of a global, randomized, phase 3 clinical trial [J]. J Thorac On- col,2012,7(3) :567 -573.
  • 9Dansin E, Cinieri S, Garrido P, et al. MO19390 (SAIL) : bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC [ J]. Lung Cancer,2012,76 (3) :373 - 379.
  • 10Su KY, Chen HY, Li KC, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer [ J ]. J Clin Oncol, 2012,30(4) :433 -440.

共引文献36

同被引文献11

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部